In case you missed this:
Simulations Plus, Inc. (SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today released preliminary revenues for its first fiscal quarter of fiscal year 2014, ended November 30, 2013 (1QFY14).
Mr. John R Kneisel, chief financial officer of Simulations Plus, stated, “In accordance with our policy to release timely financial information to our shareholders, we are releasing preliminary revenues for 1QFY14. Net income will not be known until income taxes have been determined and our auditors review our Quarterly Report on Form 10-Q. We expect to file our 10-Q with the U.S. Securities and Exchange Commission on or before the January 14, 2014 deadline.”
Preliminary results for the quarter:
This was the Company’s 25th consecutive profitable quarter, and the 47th of the last 49 quarters
Preliminary revenues increased to $2.630 million, compared to $2.290 million in 1QFY13
This represents an increase of 14.9% over 1QFY13 and is a new record 1st quarter
Approximately 20.8% of revenues came from new software licenses
Approximately 5.4% of revenues came from consulting studies and collaborations
Cash as of November 30, 2013 was $10.5 million
John DiBella, vice president for marketing and sales of Simulations Plus, said: “Fiscal year 2014 is off to a strong start, with double-digit growth in revenues according to our preliminary numbers. As was mentioned in earlier press releases, the large upgrade order from a top-5 pharmaceutical company that slipped from 4QFY13 was recognized this quarter; however, removing it would still result in a 10% increase compared to 1QFY13. Revenue from new software licenses was robust, with significant growth seen in Asian territories. Our funded collaborations have been successfully completed, resulting in a revenue reduction of $111,000 compared to 1QFY13. This reduction was partially offset by a 46% increase in consulting studies, from $96,000 to $141,000
#$%$ - Agree with your stm however, from cc they did say that not all of the $180k will be booked in Q1 due to the gov't shutdown effect. So, some $$ amt will be booked into Q2.
Well, we've breached the $5 level and should stay there or go higher depending on Qtr results and news of the COX2 inhibitor work. Nice to see the increase in dividend!!
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that its Board of Directors has decided to distribute an increased cash dividend in November.
In February 2012, the Board declared a planned ongoing dividend of $0.05 per share per quarter and dividends were distributed on March 1, May 8, August 10, and November 13, 2012. In December 2012, the Company declared an accelerated dividend distribution of $0.14 per share, consisting of the planned $0.05 per share dividend for February 2013 plus an additional $0.03 per share for the expected May, August, and November 2013 distributions. The board subsequently increased the May and August 2013 distributions by 50%, from the planned $0.02 to $0.03 per share, and dividends were distributed on May 10, and August 15, 2013. The board has now increased the planned November distribution by 100%, from $0.02 per share to $0.04 per share. This dividend will be distributed on Friday, November 15, 2013, for shareholders of record as of Friday, November 8, 2013.
Ms. Momoko Beran, chief financial officer of Simulations Plus, said: “The board has decided to increase the dividend to shareholders again this quarter as a result of our continued excellent financial performance during fiscal year 2013. Our cash as of today is about $10.9 million, and this dividend distribution will use about $640,000, so cash is expected to remain above $10 million.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, “The Board of Directors has once again demonstrated that it believes in rewarding our loyal shareholders by returning a portion of our excess cash in the form of dividends. Of course, the board always has the discretion of discontinuing or decreasing the dividend in accordance with the cash needs of the business.”
Recent Shareholder questions and answers:
Q: Do you register each planned stock sale by officers with the SEC?
A: Yes, every time as required by law.
Q: Why don't you get audited?
A: Its expensive and time-consuming, but we will likely do so in the future, and have been in the past.
Q: Why do some apps come out fast and others take a while.
A: Sometimes we have to wait for approved content, sometimes certain apps are more complicated and take more time. We have released more apps than nearly any other developer in the world.
Q: Why don't you move to a higher exchange?
A: We have talked about it with various parties and may do so in the future, it is an expensive and time-consuming process, but its one of our goals.
Q: Do you share revenues with content clients, if so how much?
A: Yes in most but not all cases, and each deal is different.
Q: When do you put out News?
A: When it happens.
Q: How much content do you have signed and potentially available for AppFlix?
A: Thousands of titles in most major categories, and we can get more.
Q: Does IR respond to every question in a timely manner?
A: Yes, we usually respond to every question within 24 hours.
Q: Will you ever sell the company?
A: Possibly, if the offer is good enough to take care of all our existing shareholders and clients, but is not something we are actively pursuing. We like what we do.
Q: Whats the general plan and some of the goals for 2014?
A: Obtain quality funding, consolidation of certain parts of our app portfolio and expanding other areas, release and major marketing of AppFlix..and signing higher tier content.
Q: Will you change the name?
A: Not sure yet, if we do it will be after the holidays most likely.
We are in late-stage talks to with a major software company to co-release our upcoming AppFlix media app. Although we have the capability to release the app using only our in-house technology, we are considering taking on a partner to expedite development of this project.
The company is question has deals with numerous major studios and networks, as well as top publishers, and we have worked with them in the past. Our goal is to have some form of the app out by the holidays but there is no official release date, and it may come out later.
Zukav App is about 95% done and it should come out soon, when Apple released iOS7 recently it set us back a bit because we had to reprogram in order to conform to new guidelines.
Funding is looking promising and we have a significant offer on the table, we will likely sign some form of a deal after the holiday rush, but right now we are gearing up what looks to be our busiest season ever.
The last we heard about the BBC deal is they are still going over the contract after multiple back and forth revisions, and we haven't gotten and official yes or no yet.
Apparently there are many people involved in the vetting process.
In general, unless we specifically state otherwise, most deals and projects are still in the works at various stages and we are waiting on other parties to move forward.
Simulations Plus, Inc. (SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that the U.S. Food and Drug Administration has added licenses of GastroPlus™ for use in the Office of Clinical Pharmacology.
John DiBella, vice president of marketing and sales for Simulations Plus, said: “Over the years, Simulations Plus’ software has been utilized heavily by the FDA to support research by several divisions, including the Office of Generic Drugs, the Center for Food Safety and Applied Nutrition, and the Center for Veterinary Medicine. Now, several licenses of GastroPlus will be available exclusively for scientists in the Office of Clinical Pharmacology (OCP). This division is responsible for the analysis of clinical data, with emphasis on the study of population variability (in both healthy and patient subject groups) and drug-drug interactions. The use of physiologically based pharmacokinetic (PBPK) modeling to assist with various facets of clinical research is becoming more widespread, and we are excited that GastroPlus, with its industry-leading capabilities, will be applied by the division in these areas.”
Dr. Viera Lukacova, team leader for simulation technologies at Simulations Plus, added: “Our group will be hosting a GastroPlus workshop for OCP scientists in the coming months, with over 35 already confirming their attendance. We look forward to training them on the use of the software and helping them to learn how it can be improved to help the agency in their recent initiative to incorporate modeling & simulation in the evaluation and approval of new medicines.”
Still a good PPS level to get in at. Look at IHUB board, particularly Storm's messages for factual (not opiniated) look.